At present, the PD1/PD-L1 pathway is a hotspot of tumor immunity, and we confirmed by the SRAMP database that the retrieval of PRMT5 and PD-L1 can indeed modify m6A methylation in multiple sites, so we can speculate that METTL3 by methylation modification regulates the expression of PRMT5 and PD-L1. This evidence concerns the gene CD274 and neoplasm.